ClinicalTrials.gg
Enrolling by invitationNCT06688175Updated Aug 7, 2025

IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma

A Phase 2 interventional study of IMRT combined with lobaplatin-based concurrent chemotherapy in Nasopharyngeal Neoplasms, Elderly and Chemotherapy, sponsored by The First Affiliated Hospital of Xiamen University. Enrolling by invitation at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by The First Affiliated Hospital of Xiamen University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Nasopharyngeal Neoplasms with a site in China — 22 open to participants now, 30 under way, 6 of them phase 3. Nasopharyngeal Neoplasms · China.

Planned enrollment
62nd of 73
32 · median 100
Started
2024
with 5 others
Phase 2
33 of 83
10 open now
Primary completion
2026-12
later than 15 of 29 live
Registered
71st of 83
by date
Lead sponsor
3 of 83
The First Affiliated Hospital of Xiamen University

Among the 83 studies in Nasopharyngeal Neoplasms with a site in China, this one is the 62nd largest by planned enrollment of the 73 interventional ones that give a count, is one of 6 that started in 2024, is one of 33 in phase 2, reaches primary completion later than 15 of the 29 other live ones, and was the 71st registered.

Nasopharyngeal Neoplasms

226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.

Browse Nasopharyngeal Neoplasms studies →

Open to participants now

22 of the 83 studies in Nasopharyngeal Neoplasms with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasopharyngeal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This prospective, multicenter, single-arm, open-label phase II clinical study aimed to investigate the efficacy and safety of intensity-modulated radiotherapy combined with lobaplatin-based concurrent chemotherapy in the treatment of elderly patients with nasopharyngeal carcinoma

Read the detailed description

Lobaplatin, as a third-generation platinum-based chemotherapeutic agent, demonstrates equivalent therapeutic efficacy to cisplatin but significantly lower toxicity. Preliminary clinical trials have confirmed that lobaplatin shows substantial effectiveness in treating various cancers including breast cancer, esophageal cancer, colorectal cancer, and cervical cancer. Importantly, lobaplatin does not exhibit cross-resistance with cisplatin or carboplatin, indicating a promising application prospect.

Currently, lobaplatin has demonstrated clear efficacy in non-elderly nasopharyngeal carcinoma (NPC) chemotherapy. Guo Xiang et al. have confirmed that for non-elderly NPC patients, induction chemotherapy with lobaplatin followed by concurrent chemoradiotherapy may be a treatment option for locally advanced NPC. However, there is very limited research reporting on the use of lobaplatin in elderly NPC patients.

Based on the above theoretical considerations and our research results, lobaplatin shows good safety and reliable efficacy in treating elderly NPC, with minimal gastrointestinal reactions and low incidence of renal, neurotoxic, and ototoxic effects. This approach significantly enhances the quality of life for locally advanced elderly NPC patients. Therefore, the efficacy and safety of lobaplatin in concurrent chemotherapy for elderly NPC deserve further investigation. This study aims to evaluate the recent efficacy, safety, and toxic side effects of lobaplatin combined with intensity-modulated radiotherapy in the treatment of elderly NPC. Designed as a multicenter, open-label, prospective study, it aims to verify whether lobaplatin is an effective concurrent chemotherapeutic agent for elderly NPC, while further improving the quality of life for these patients under guarantees of therapeutic efficacy.

03

Conditions studied

  • Nasopharyngeal Neoplasms
  • Elderly
  • Chemotherapy
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma;
  • Stage II-IVa (UICC 8th edition);
  • Acceptable induction chemotherapy and Tarceva targeted therapy;
  • No history of other malignant tumors;
  • Male or female, aged 65-80 years.
  • Liver function: Total ≤ (ULN); and ALT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 5 times ULN;
  • Renal function: ≥ 60 ml/min or Creatinine ≤ 1.5 × ULN;
  • Hematological tests: (ANC) ≥ 2 × 10\^9/L, count ≥ 100 × 10\^9/L, and ≥ 9 g/dL;
  • No severe dysfunction of vital organs such as heart and lung;
  • PS score ≤ 2 points

Exclusion criteria

Exclusion Criteria:

  • Distant detected before treatment;
  • Refusal to sign the form;
  • Patients who cannot comply with regular follow-up due to psychological, social, family, or geographical reasons;
  • Simultaneously receiving other experimental treatments in clinical trials (during the treatment phase of clinical research);
  • Severe, uncontrolled infections or medical conditions;
  • Vital organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy and chemotherapy;
  • Laboratory tests: Total > (ULN); and/or ALT > 1.5 times ULN with alkaline phosphatase > 2.5 times ULN;
  • Factors affecting drug administration, distribution, metabolism, and excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.;
  • Long-term use of after organ transplantation;
  • Patients with a history of other malignant tumors before enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Experimental

    in the treatment of elderly patients with nasopharyngeal carcinoma

    Drug: IMRT combined with lobaplatin-based concurrent chemotherapy

Interventions

  • DrugIMRT combined with lobaplatin-based concurrent chemotherapy

    IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy

06

What researchers measure

Primary outcomes

  1. objective response rate (ORR)

    ORR encompasses both CR and PR.

    Time frame: 6 months

Secondary outcomes

  1. Safety

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 3 months

  2. Overall survival (OS)

    OS was defined as the time of NPC diagnosis until death from any cause.

    Time frame: 3 years

  3. Locoregional relapse-free survival (LRFS)

    LRFS was measured as the duration time from the diagnosis of nasopharyngeal carcinoma to the occurrence of relapse in the nasopharynx or neck lymph nodes or until the last follow-up.

    Time frame: 3 years

  4. Distant metastasis-free survival (DMFS)

    DMFS was defined as the duration time of nasopharyngeal carcinoma diagnosis to the time of distant metastasis or the last follow-up.

    Time frame: 3 years

  5. Progression-free survival (PFS)

    PFS was referred to as the time from nasopharyngeal carcinoma diagnosis to the date of disease progression.

    Time frame: 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 33 phase 2 interventional studies under Nasopharyngeal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 124. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06688175
Responsible party
San-Gang Wu (Clinical Professor, The First Affiliated Hospital of Xiamen University) — Principal investigator
First posted
Nov 14, 2024
Start date
Nov 13, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 7, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion